WPI Bioengineering Institute to Hold Annual Corporate Forum March 25

Keynote by Kevin O’Sullivan, President, Massachusetts Biomedical Initiatives
Media Contact
March 19, 2009

What

Getting from discovery to commercial product for new therapeutics or medical devices is an increasingly segmented process, with universities and companies focused on core-competencies along the development chain. As a result, the roles of service providers, alliances and partnerships continue to grow in scope and complexity in the pharmaceutical, biotechnology and bioengineering industries. Speakers from a range of companies will discuss their respective roles in the development chain and how they interact with other companies and universities.

When

Wednesday, March 25, 2009, from 1 p.m. to 5 p.m.

Where

WPI Campus Center Odeum (On Main Campus)

Presenters

AVATAR: Judy Carmody, Ph.D., President

Charles River Labs: Cheri Walker, Ph.D., Senior Vice President

Crescent Innovations Inc.: Al Prescott, President

Intertech Engineering Associates Inc.: David Vogel, Ph.D., President

Blue Sky Biotech: Norman Garceau, Ph.D., President & Chief Scientific Officer

Keynote

Kevin O'Sullivan, President, Massachusetts Biomedical Initiatives

About BEI

The WPI Bioengineering Institute is an interdisciplinary research and development organization blending academic, industry, and government partnerships to develop and commercialize innovative, life sciences-based technologies. In BEI's seven multidisciplinary centers, scientists, engineers, and clinicians address important research challenges in several major areas of medical technology and healthcare, including bioprocessing, imaging, nanotechnology, remote diagnostics and treatment, sensing, and water quality.